AUTHORS
Shai Shimony, MD, MPH, Jose Tinajero, PharmD2, Kuo-Kai Chin, MD3, Matthew Rees, MD4, Joseph Fleming5, Lorena Lopez-Gonzalez, PhD6, Sneha Kelkar7, Shweta Kamat8, Kyle Roney9, Ashley Cooper10, Craig Freyer, PharmD, BCOP11, Huan Huang, PhD12, Marlise Rachael Luskin, MD, MSCE13, Aaron D Goldberg, MD, PhD14, Ibrahim Aldoss, MD15
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Syndax Pharmaceuticals, Inc., New York, New York, United States
7 OPEN Health, New York, New York, United States
8 OPEN Health, New York, New York, United States
9 OPEN Health, New York, New York, United States
10 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
11 Syndax Pharmaceuticals, Inc., New York, New York, United States
12 Syndax Pharmaceuticals, Inc., New York, New York, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Background: Revumenib, a first-in-class, oral, potent, and selective menin inhibitor, is used for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an NPM1 mutation (NPM1m) or R/R acute leukemia (AL) harboring a KMT2A translocation in adult and pediatric patients (pts) ≥1 year. Real‑world evidence complements clinical trial findings by showing how treatments are used and perform among broader patient populations in routine clinical practice. ROAR (Real-world Outcomes for Acute leukemia treated with Revumenib) is an ongoing multicenter, longitudinal real-world study assessing the effectiveness and safety of revumenib in pts with AL in the US. Initial results, based on a single-center cohort, were recently presented (Shimony et al. EHA 2026).
Aim: To present real-world treatment patterns and outcomes based on a multicenter cohort of pts with R/R AL treated with revumenib at 3 large academic centers.
Methods: Pts with R/R AL who received ≥1 dose of revumenib outside of a clinical trial are followed from revumenib initiation until data cutoff (31May2026) or death. The overall response rate (ORR) includes complete remission (CR), CR with partial hematologic recovery (CRh), CR with incomplete hematologic recovery (CRi), morphologic leukemia-free state (MLFS), and partial response (PR). Composite CR (CRc) includes CR, CRh, and CRi. Responses were evaluated in pts who completed ≥1 treatment cycle (response-evaluable population). Time-to-event analyses (overall survival [OS], event-free survival [EFS], duration of response [DOR]) were conducted. Safety outcomes include grade ≥3 QTcF prolongation and differentiation syndrome (DS) observed from revumenib initiation to 14 days after discontinuation. OS, EFS, and safety were evaluated in the overall population.
Results: Overall, 47 pts were included in this analysis (AML, n=39; ALL, n=6; MPAL, ALAL, or undifferentiated AL, n=2) with a median follow-up of 4.7 mo (range, 0.3–25.0). Thirty-one pts had a KMT2A translocation, 11 had an NPM1m, 1 had a KMT2A-PTD, 1 had a NUP98 rearrangement, and 3 had other genetic aberrations associated with HOX overexpression (SET-NUP214, XPO-MLLT10, PICALM::MLLT10). Median age at revumenib initiation was 39 years (IQR, 38; Q1-Q3: 29–67); 89% were White; and 60% were female. Median number of prior lines of therapy was 2 (range, 1–8); 68% had prior venetoclax exposure; and 32% had a prior hematopoietic stem cell transplant (HSCT). Eighteen pts (38%) received revumenib monotherapy; 29 (62%) received combination therapy (most common was revumenib + venetoclax + hypomethylating agent).
Among the response-evaluable population (n=41; 17 monotherapy, 24 combination therapy), ORR was 66% (27/41) and CRc rate was 49% (20/41). ORR was 71% (17/24) with combination therapy and 59% (10/17) with monotherapy; CRc rates were 54% (13/24) and 41% (7/17), respectively. Best overall response was CR in 29% (12/41), CRh in 12% (5/41), CRi in 7% (3/41), MLFS in 12% (5/41), and PR in 5% (2/41). Median (range) time to first and best response was 1.1 mo (0.1–12.2) and 1.3 mo (0.1–12.2), respectively (1.3 and 1.4 mo for monotherapy; 1.0 and 1.1 mo for combination therapy). Median DOR was 4.9 mo (range, 0.5–23.9). Among the overall population, ORR was 57% (27/47) and CRc rate was 43% (20/47). Fourteen responders proceeded to HSCT (30%; 4 monotherapy, 10 combination therapy; 3 as second HSCT); 4/14 pts resumed revumenib as post-HSCT maintenance.
Among the overall population, the estimated median OS from revumenib initiation was 8.1 mo (95% CI, 5.8–12.0) and estimated median EFS was 6.6 mo (95% CI, 3.5–9.9).
One pt experienced grade 3 QTcF prolongation which resolved after discontinuation of concomitant QTc–prolonging medication without dose reduction, interruption, or discontinuation of revumenib. Three pts had grade 3 DS (2 interruptions, 1 discontinuation; 2 monotherapy, 1 combination therapy).
Conclusions: In this expanded interim analysis of the ROAR study, revumenib demonstrated meaningful real‑world clinical activity and a manageable safety profile in heavily pretreated pts with R/R AL from 3 large academic centers. Responses were frequent, rapid, and observed with both monotherapy and combination regimens, with numerically higher response rates in combination-treated pts. Importantly, nearly 1/3 of pts were bridged to HSCT. Overall, these data support revumenib as an effective therapeutic option for R/R KMT2Ar and NPM1m AL in routine clinical practice.
DISCLOSURES
Shai Shimony, MD, MPH: Syndax - Research Funding